Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer

Open access
Kim, Edward J., Ben‐Josef, Edgar, Herman, Joseph M., Bekaii‐Saab, Tanios, Dawson, Laura A., Griffith, Kent A., Francis, Isaac R., Greenson, Joel K., Simeone, Diane M., Lawrence, Theodore S., Laheru, Daniel, Wolfgang, Christopher L., Williams, Terence, Bloomston, Mark, Moore, Malcolm J., Wei, Alice, Zalupski, Mark M. · 2013 · Cancer

Abstract

BACKGROUND: The purpose of this study was to evaluate preoperative treatment with full‐dose gemcitabine, oxaliplatin, and radiation therapy (RT) in patients with localized pancreatic cancer. METHODS: Eligibility included confirmation of adenocarcinoma, resectable or borderline resectable disease, a performance status ≤2, and adequate organ function. Treatment consisted of two 28‐day cycles of gemcitabine (1 g/m 2 over 30 minutes on days 1, 8, and 15) and oxaliplatin (85 mg/m 2 on days 1 and 15) with RT during cycle 1 (30 Gray [Gy] in 2‐Gy fractions). Patients were evaluated for surgery after cycle 2. Patients who underwent resection received 2 cycles of adjuvant chemotherapy. RESULTS: Sixty‐eight evaluable patients received treatment at 4 centers. By central radiology review, 23 patients had resectable disease, 39 patients had borderline resectable disease, and 6 patients had unresectable disease. Sixty‐six patients (97%) completed cycle 1 with RT, and 61 patients (90%) completed cycle 2. Grade ≥3 adverse events during preoperative therapy included neutropenia (32%), thrombocytopenia (25%), and biliary obstruction/cholangitis (14%). Forty‐three patients underwent resection (63%), and complete (R0) resection was achieved in 36 of those 43 patients (84%). The median overall survival was 18.2 months (95% confidence interval, 13–26.9 months) for all patients, 27.1 months (95% confidence interval, 21.2–47.1 months) for those who underwent resection, and 10.9 months (95% confidence interval, 6.1–12.6 months) for those who did not undergo resection. A decrease in CA 19‐9 level after neoadjuvant therapy was associated with R0 resection (P = .02), which resulted in a median survival of 34.6 months (95% confidence interval, 20.3–47.1 months). Fourteen patients (21%) are alive and disease free at a median follow‐up of 31.4 months (range, 24–47.6 months). CONCLUSIONS: Preoperative therapy with full‐dose gemcitabine, oxaliplatin, and RT was feasible and resulted in a high percentage of R0 resections. The current results are particularly encouraging, because the majority of patients had borderline resectable disease. Cancer 2013;119:2692–2700. © 2013 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.28117

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 182

Metadata

Authors
Kim, E. J., Ben‐Josef, E., Herman, J. M., Bekaii‐Saab, T., Dawson, L. A., Griffith, K. A., Francis, I. R., Greenson, J. K., Simeone, D. M., Lawrence, T. S., Laheru, D., Wolfgang, C. L., Williams, T., Bloomston, M., Moore, M. J., Wei, A., & Zalupski, M. M.
Venue
Cancer
Publisher
Wiley
Published
2013-05-29
Volume
119
Issue
15
Pages
2692-2700
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1498143967
Cited by
182
References
2
FWCI
10.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. https://app.cochat.ai/papers/10.1002/cncr.28117
The paper
Kim, E. J., Ben‐Josef, E., Herman, J. M., Bekaii‐Saab, T., Dawson, L. A., Griffith, K. A., Francis, I. R., Greenson, J. K., Simeone, D. M., Lawrence, T. S., Laheru, D., Wolfgang, C. L., Williams, T., Bloomston, M., Moore, M. J., Wei, A., & Zalupski, M. M. (2013). A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. https://doi.org/10.1002/cncr.28117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.